- Founded
- 2021
- Employees*
- 10
- Funding to Date*
- $1,433,300
- Website
- www.aimalaboratories.com
Globally, one in ten women will suffer from endometriosis, a painful and debilitating gynecological condition. On average, women don’t get a proper diagnosis for five to twelve years after the onset of symptoms because, until now, the only reliable way to do so was via laparoscopic surgery that can cost over $20,000 and require three months of recovery. Moreover, endometriosis symptoms overlap with 25 other conditions, meaning undiagnosed women face years of costly trial-and-error treatment.
Afynia has created the first and only patented blood test for diagnosing endometriosis early. It returns a result in days, not years, and will be offered through clinics and home collection kits beginning in 2024. Based on decades of research by co-founders Dr. Lauren Foster, PhD, and Dr. Jocelyn Wessels, PhD, former academics at McMaster University in Ontario, Canada, the endometriosis test is just the beginning. Afynia is building a digital women’s health platform that will provide diagnostics, virtual care, and prescription deliveries for endometriosis and other conditions.
For too long, the world has normalized and undertreated chronic pelvic pain. With Afynia, women have the opportunity to become full-fledged partners in their own healthcare.